BrainsWay Deep TMS therapy has been tested in over 60 clinical studies, for various clinical indications, in leading institutions worldwide.
The FDA has cleared this BrainsWay Deep TMS therapy for treatment resistant depression and it is currently available in the U.S., Europe, and South America.
BrainsWay is also indicated by the FDA as an intended adjunct treatment for adult patients suffering from Obsessive Compulsive Disorder (OCD)/FDA De Novo.
